USD 2.5
(0.4%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 | 553.97 Thousand USD | 29.96% |
2023 | 426.27 Thousand USD | -65.94% |
2022 | 1.25 Million USD | -55.92% |
2021 | 2.83 Million USD | 5.02% |
2020 | 2.7 Million USD | -41.37% |
2019 | 4.61 Million USD | 35.57% |
2018 | 3.4 Million USD | 47.12% |
2017 | 2.31 Million USD | 191.19% |
2016 | 793.98 Thousand USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q3 | 132.81 Thousand USD | -28.44% |
2024 Q1 | 144.17 Thousand USD | -57.17% |
2024 Q4 | 132.81 Thousand USD | 0.0% |
2024 FY | 553.97 Thousand USD | 29.96% |
2024 Q2 | 185.59 Thousand USD | 28.73% |
2023 Q2 | 89.68 Thousand USD | 100.0% |
2023 Q4 | 336.58 Thousand USD | 100.0% |
2023 Q3 | 168.29 Thousand USD | 87.65% |
2023 Q1 | 44.84 Thousand USD | 100.29% |
2023 FY | 426.27 Thousand USD | -65.94% |
2022 Q1 | 161.97 Thousand USD | 101.27% |
2022 Q4 | -15.53 Million USD | -3448.21% |
2022 Q2 | 323.95 Thousand USD | 100.0% |
2022 Q3 | 463.84 Thousand USD | 43.18% |
2022 FY | 1.25 Million USD | -55.92% |
2021 Q3 | 9307.00 USD | -99.34% |
2021 Q4 | -12.76 Million USD | -137284.89% |
2021 FY | 2.83 Million USD | 5.02% |
2021 Q2 | 1.41 Million USD | 0.0% |
2021 Q1 | 1.41 Million USD | -47.83% |
2020 Q2 | 1.83 Million USD | 100.0% |
2020 Q3 | 432.15 Thousand USD | -76.51% |
2020 FY | 2.7 Million USD | -41.37% |
2020 Q1 | 919.69 Thousand USD | -80.06% |
2020 Q4 | 2.7 Million USD | 525.63% |
2019 Q1 | 1.33 Million USD | 64.94% |
2019 FY | 4.61 Million USD | 35.57% |
2019 Q3 | 966.42 Thousand USD | -63.92% |
2019 Q2 | 2.67 Million USD | 100.0% |
2019 Q4 | 4.61 Million USD | 377.18% |
2018 FY | 3.4 Million USD | 47.12% |
2018 Q3 | 2.58 Million USD | 212.36% |
2018 Q4 | 812.03 Thousand USD | -68.64% |
2018 Q1 | 829 Thousand USD | 33.93% |
2018 Q2 | 829 Thousand USD | 0.0% |
2017 Q4 | 618.98 Thousand USD | 0.0% |
2017 FY | 2.31 Million USD | 191.19% |
2016 FY | 793.98 Thousand USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Collegium Pharmaceutical, Inc. | 326.16 Million USD | 99.83% |
Embecta Corp. | 749.9 Million USD | 99.926% |
ANI Pharmaceuticals, Inc. | 305.3 Million USD | 99.819% |
Dynavax Technologies Corporation | 182.11 Million USD | 99.696% |
Esperion Therapeutics, Inc. | 73.06 Million USD | 99.242% |
Pacira BioSciences, Inc. | 490.3 Million USD | 99.887% |
PainReform Ltd. | -15 Thousand USD | 3793.14% |
Aquestive Therapeutics, Inc. | 29.75 Million USD | 98.138% |
Sunshine Biopharma, Inc. | 8.33 Million USD | 93.357% |
SCYNEXIS, Inc. | 124.51 Million USD | 99.555% |
Cosmos Health Inc. | 4.34 Million USD | 87.264% |
Journey Medical Corporation | 52.52 Million USD | 98.945% |
Sunshine Biopharma, Inc. | 8.33 Million USD | 93.357% |
Safety Shot Inc | -74.45 Thousand USD | 844.015% |
Alpha Teknova, Inc. | 10.29 Million USD | 94.62% |
Intra-Cellular Therapies, Inc. | 430.62 Million USD | 99.871% |
Bright Green Corporation | -237.01 Thousand USD | 333.727% |
Procaps Group, S.A. | 239.56 Million USD | 99.769% |
Theratechnologies Inc. | 62.12 Million USD | 99.108% |
Harrow Health, Inc. | 90.55 Million USD | 99.388% |
Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | 88.325% |
Biofrontera Inc. | 16.62 Million USD | 96.668% |
DURECT Corporation | 6.83 Million USD | 91.89% |
Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 99.894% |
Cronos Group Inc. | 6.99 Million USD | 92.076% |
OptiNose, Inc. | 62.35 Million USD | 99.112% |
Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 99.874% |
Kala Pharmaceuticals, Inc. | -303 Thousand USD | 282.829% |
RedHill Biopharma Ltd. | 3.05 Million USD | 81.862% |
Organogenesis Holdings Inc. | 309.79 Million USD | 99.821% |
Guardion Health Sciences, Inc. | 5.39 Million USD | 89.731% |
Cumberland Pharmaceuticals Inc. | 33.48 Million USD | 98.346% |
Radius Health, Inc. | 307.71 Million USD | 99.82% |
Universe Pharmaceuticals INC | 10.07 Million USD | 94.503% |
ProPhase Labs, Inc. | 16.23 Million USD | 96.589% |
Phibro Animal Health Corporation | 312.48 Million USD | 99.823% |
Procaps Group S.A. | 239.56 Million USD | 99.769% |
Alvotech | -69.42 Million USD | 100.798% |
TherapeuticsMD, Inc. | 1.3 Million USD | 57.452% |
Viatris Inc. | 6.43 Billion USD | 99.991% |
Rockwell Medical, Inc. | 8.7 Million USD | 93.635% |
Aytu BioPharma, Inc. | 54.58 Million USD | 98.985% |
SIGA Technologies, Inc. | 122.09 Million USD | 99.546% |
Tilray Brands, Inc. | 223.35 Million USD | 99.752% |
Lifecore Biomedical, Inc. | 41.85 Million USD | 98.676% |
Shineco, Inc. | 882.16 Thousand USD | 37.203% |
PetIQ, Inc. | 252.74 Million USD | 99.781% |
Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 174.3% |
Incannex Healthcare Limited | 12 Thousand USD | -4516.425% |
Neurocrine Biosciences, Inc. | 1.84 Billion USD | 99.97% |
Alimera Sciences, Inc. | 61.17 Million USD | 99.094% |
Silver Spike Investment Corp. | 8.1 Million USD | 93.163% |
Assertio Holdings, Inc. | 125.04 Million USD | 99.557% |
Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 8233.475% |
Petros Pharmaceuticals, Inc. | 4.19 Million USD | 86.782% |
Clever Leaves Holdings Inc. | 6.55 Million USD | 91.55% |
Cyclo Therapeutics, Inc. | -2.41 Million USD | 122.985% |
Avadel Pharmaceuticals plc | 27.11 Million USD | 97.957% |
Hempacco Co., Inc. | -1.21 Million USD | 145.563% |
Talphera, Inc. | -4.89 Million USD | 111.317% |
Alvotech | -69.42 Million USD | 100.798% |
Eagle Pharmaceuticals, Inc. | 221.67 Million USD | 99.75% |
Lantheus Holdings, Inc. | 709.54 Million USD | 99.922% |
Currenc Group, Inc. | 17.35 Million USD | 96.808% |
Kamada Ltd. | 52.59 Million USD | 98.947% |
Indivior PLC | 907 Million USD | 99.939% |
Evoke Pharma, Inc. | 4.97 Million USD | 88.873% |
Flora Growth Corp. | 17.73 Million USD | 96.877% |
Cyclo Therapeutics, Inc. | -2.41 Million USD | 122.985% |
Evolus, Inc. | 140.52 Million USD | 99.606% |
HUTCHMED (China) Limited | 453.55 Million USD | 99.878% |
Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 99.839% |
Akanda Corp. | 111.44 Thousand USD | -397.062% |